Leukemia News

The FDA announced several regulatory actions the past few weeks.

This year’s ASH Annual Meeting and Exposition spotlighted practice-changing research in malignant and benign hematology.

NEW ORLEANS — Utilization of hematopoietic stem cell transplantation for acute myeloid leukemia has increased over time but remains far below optimal levels, according to study results presented at ASH Annual Meeting and Exposition.

Shannon L. Maude, MD, PhD, always knew she wanted to work with children — she just didn’t always know how she could best help them.

Speed matters when it comes to treatment of highly aggressive cancers.

NEW ORLEANS — In this video, Aaron T. Gerds, MD, MS, discusses a study presented at the ASH Annual Meeting and Exposition, which evaluated a 7-day regimen of venetoclax and azacytidine in patients with treatment-naive acute myeloid leukemia.

NEW ORLEANS — In this video perspective, Aaron T. Gerds, MD, MS, discusses a study presented at the ASH Annual Meeting and Exposition comparing daunorubicin regimens for patients with newly diagnosed acute myeloid leukemia. "This study randomized folks between 90 mg/m2 and 60 mg/m2 of daunorubicin and it turned out 60 mg/m2 wasn't any worse," Gerds said, noting, however, that 60 mg/m2 may be associated with more toxicity.

NEW ORLEANS — In this video, Aaron T. Gerds, MD, MS, assistant professor at the Cleveland Clinic Taussig Cancer Institute, discusses updated results from the Momentum phase 3 study presented at the ASH Annual Meeting and Exposition.

An increasing number of oral anticancer drugs have been granted FDA approval and introduced into clinical practice.

NEW ORLEANS — Abhay Singh, MD, MPH, of the Cleveland Clinic discusses the results of a study presented here on therapy-related risk factors for the development of myelodysplastic syndrome and acute myeloid leukemia in cancer survivors.